NF-κB inhibitors that prevent foam cell formation and atherosclerotic plaque accumulation

被引:39
|
作者
Plotkin, Jesse D. [1 ]
Elias, Michael G. [1 ]
Dellinger, Anthony L. [1 ]
Kepley, Christopher L. [1 ]
机构
[1] Univ North Carolina Greensboro, Joint Sch Nanosci & Nanoengn, Greensboro, NC USA
关键词
Atherosclerosis; NF-kappa B; Foam cells; Fullerenes; Low-density lipoprotein; FULLERENE NANOMATERIALS INHIBIT; ACTIVATED MAST-CELLS; MYOCARDIAL-INFARCTION; SCAVENGER RECEPTOR; CORONARY PLAQUES; OXIDATIVE STRESS; SHOULDER REGION; MONOCYTIC CELLS; TNF-ALPHA; CD36;
D O I
10.1016/j.nano.2017.04.013
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
The transformation of monocyte-derived macrophages into lipid-laden foam cells is one inflammatory process underlying atherosclerotic disease. Previous studies have demonstrated that fullerene derivatives (FDs) have inflammation-blunting properties. Thus, it was hypothesized that FD could inhibit the transformation process underlying foam cell formation. Fullerene derivatives inhibited the phorbolmyristic acid/oxidized low-density lipoprotein-induced differentiation of macrophages into foam cells as determined by lipid staining and morphology. Lipoproteininduced generation of TNF-alpha, C5a-induced MC activation, ICAM-1 driven adhesion, and CD36 expression were significantly inhibited in FD treated cells compared to non-treated cells. Inhibition appeared to bemediated through theNF-kappa Bpathway as FDreduced expression ofNF-kappa Band atherosclerosis-associated genes. Compared to controls, FDdramatically inhibited plaque formation in arteries of apolipoprotein E null mice. Thus, FD may be an unrecognized therapy to prevent atherosclerotic lesions via inhibition of foam cell formation and MC stabilization. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:2037 / 2048
页数:12
相关论文
共 50 条
  • [31] Co-Delivery of Curcumin and Bioperine via PLGA Nanoparticles to Prevent Atherosclerotic Foam Cell Formation
    Pillai, Sindhu C.
    Borah, Ankita
    Le, Minh Nguyen Tuyet
    Kawano, Hiroaki
    Hasegawa, Kouichi
    Kumar, D. Sakthi
    PHARMACEUTICS, 2021, 13 (09)
  • [32] NF-κB signaling and bone formation
    Wang, C. -Y.
    BONE, 2012, 50 : S22 - S22
  • [33] Role of NF-κB and gene targets of NF-κB in glioma cell plasticity
    Friedmann-Morvinski, Dinorah
    Narasimamurthy, Rajesh
    Xia, Yifeng
    Myskiw, Chad
    Soda, Yasushi
    Verma, Inder M.
    CANCER RESEARCH, 2015, 75
  • [34] Inhibitors of NF-κB derived from thalidomide
    De-Blanco, Esperanza J. Carcache
    Pandit, Bulbul
    Hu, Zhigen
    Shi, Handong
    Lewis, Andrew
    Li, Pul-Kai
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (21) : 6031 - 6035
  • [35] Bicyclic Cyclohexenones as Inhibitors of NF-κB Signaling
    Hexum, Joseph K.
    Tello-Aburto, Rodolfo
    Struntz, Nicholas B.
    Harned, Andrew M.
    Harki, Daniel A.
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (06): : 459 - 464
  • [36] NF-κB Inhibitors from Eurycoma longifolia
    Thi Van Anh Tran
    Malainer, Clemens
    Schwaiger, Stefan
    Atanasov, Atanas G.
    Heiss, Elke H.
    Dirsch, Verena M.
    Stuppner, Hermann
    JOURNAL OF NATURAL PRODUCTS, 2014, 77 (03): : 483 - 488
  • [37] Inhibition of tumor growth by NF-κB inhibitors
    Umezawa, Kazuo
    CANCER SCIENCE, 2006, 97 (10) : 990 - 995
  • [38] NF-κB Inhibitors in Head and Neck Cancer
    Nagini, Siddavaram
    Tanagala, Kranthi Kiran Kishore
    Chattopadhyay, Indranil
    LETTERS IN DRUG DESIGN & DISCOVERY, 2017, 14 (05) : 619 - 633
  • [39] Inhibitors of NF-κB signaling: 785 and counting
    T D Gilmore
    M Herscovitch
    Oncogene, 2006, 25 : 6887 - 6899
  • [40] Inhibitors of NF-κB signaling:: 785 and counting
    Gilmore, T. D.
    Herscovitch, M.
    ONCOGENE, 2006, 25 (51) : 6887 - 6899